Unlike in non-small cell lung cancer (NSCLC), where well-known oncogenic drivers (e.g., VEGF, KRAS, EGFR, ALK, ROS1) can be effectively targeted with specific inhibitors [2], personalized medicine is not yet reliable in SCLC [3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.